

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/686,809	10/17/2003	Bernd Nickel	017094-0306034	8786
909	7590 12/09/200	5	EXAMINER	
PILLSBUR P.O. BOX 1	Y WINTHROP SHA	COOK, REBECCA		
MCLEAN,			ART UNIT	PAPER NUMBER
,			1614	

DATE MAILED: 12/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/686,809	NICKEL ET AL.					
Office Action Summary	Examiner	Art Unit					
	Rebecca Cook	1614					
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address -					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the application to become ABANDO	DN. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on							
2a) This action is <b>FINAL</b> . 2b) This	s action is non-final.						
3) Since this application is in condition for allowa							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>14-29</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
,	7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>14-29</u> are subject to restriction and/o	r election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examine	er.						
10)⊠ The drawing(s) filed on <u>17 October 2003</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correc							
11) The oath or declaration is objected to by the Ex	xaminer. Note the attached Office	ce Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a)⊠ All b)□ Some * c)□ None of:							
1. Certified copies of the priority documents have been received.							
<ul> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage</li> </ul>							
•	•	ived in this National Stage					
application from the International Burea  * See the attached detailed Office action for a list		ved					
See the attached detailed Office action for a list	of the defined copies her reser	<b>, 00</b> .					
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summa						
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08</li> </ul>	Paper No(s)/Mail  5) Notice of Informa	Date Il Patent Application (PTO-152)					
Paper No(s)/Mail Date	6) Other:						

Art Unit: 1614

## Election/Restrictions

Claims 14 is generic to a plurality of disclosed patentably distinct species comprising an N-substituted indol-3-glyoxylamide of Formula I. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from those disclosed in the specification or in claim 26, even though this requirement is traversed. Applicant is further required to elect an antitumor agent from those recited in claims 25 and 26.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/686,809

Art Unit: 1614

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

An attempt to reach the attorney was made on December 6, 2005 to request an oral election to the above election requirement, but was unsuccessful.

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Cook whose telephone number is (571) 272-0571. The examiner can normally be reached on Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (571) 272-0951.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Renee Jones (571) 272-0547 in Customer Service.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The official fax number is 571-273-8300.

Page 4

Rebecca Cook

Primary Examiner Art Unit 1614

December 6, 2005